Belgium-based eTheRNA Immunotherapies, a developer of immunotherapy and vaccine products for the treatment of cancer and infectious diseases, has established a new office and subsidiary in Hong Kong. eTheRNA Asia is located in the Sheung Wan area of the city.
The office will support and build on eTheRNA’s growing activities in China and the broader Asia-Pacific region. In particular, eTheRNA Asia will focus on supporting business and investor relations with its strategic partner, China Grand Pharmaceutical and Healthcare.
In a press release, chief executive officer Steven Powell said: “The strategic aim under the Healthy China 2030 plan is to improve cancer care and develop truly innovative oncology drugs in China itself. Through our Chinese investors and partners we have developed strong links with the region and look forward to increasing our activities and contributing to help fulfil this ambition.”
Naomi Davies is an FDI consultant at Investment Monitor, with expertise in location benchmarking and cross-border investment.